AL
ALXO.US Alx Oncology Holdings
- Market cap
- USD 144M
- P/E
- -
- P/B
- 1.10x
- ROE
- -52.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ALXO.US undervalued?
Graham numberThe Graham number of Alx Oncology Holdings cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alx Oncology Holdings fundamental analysis
No fundamental analysis for Alx Oncology Holdings yet.
Alx Oncology Holdings stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceutica…
Full company profileAlx Oncology Holdings financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alx Oncology Holdings annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 2.07M | 4.80M | 1.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 187K | 436K | 107K | -736K | -1.47M | -836K | -872K | - | - |
| Operating Income | -13.7M | -19.2M | -43.7M | -83.6M | -127M | -170M | -142M | -104M | -74.0M |
| EBITDA | -13.3M | -18.8M | -43.5M | -83.4M | -127M | -158M | -132M | -99.4M | -70.1M |
| Net Income | -13.7M | -19.2M | -45.7M | -83.5M | -123M | -161M | -135M | -102M | -71.8M |
| EPS | -0.63 | -0.88 | -1.15 | -2.07 | -3.03 | -3.74 | -2.58 | -1.90 | -0.53 |
| Balance Sheet | |||||||||
| Total Assets | 11.2M | 10.7M | 436M | 380M | 306M | 243M | 148M | 59.0M | 161M |
| Total Liabilities | 2.01M | 11.0M | 6.21M | 17.1M | 43.0M | 52.8M | 34.2M | 33.1M | 24.6M |
| Shareholders' Equity | 9.16M | -276K | 430M | 363M | 263M | 190M | 114M | 26.0M | 136M |
| Cash & Short-term Investments | 8.26M | 9.02M | 434M | 364M | 266M | 183M | 128M | 44.8M | 138M |
| Total Debt | - | 5.42M | - | 742K | 10.4M | 17.2M | 17.0M | 5.22M | 9.71M |
| Cash Flow | |||||||||
| Operating Cash Flow | -13.2M | -14.2M | -38.3M | -68.1M | -89.2M | -130M | -122M | -84.1M | -69.4M |
| Capital Expenditure | 653K | 353K | 31.0K | 4.92M | 1.43M | 1.27M | 447K | 212K | 134K |
| Free Cash Flow | -13.8M | -14.6M | -38.3M | -73.0M | -90.7M | -132M | -122M | -84.4M | -69.5M |
| Ratios | |||||||||
| ROE | -150.0% | - | -10.6% | -23.0% | -46.9% | -84.8% | -118.7% | -391.4% | -52.7% |
| ROA | -123.0% | -180.2% | -10.5% | -22.0% | -40.3% | -66.3% | -91.3% | -172.2% | -44.6% |
| Net Profit Margin | -664.3% | -401.2% | -3,869.7% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.00x | 0.04x | 0.09x | 0.15x | 0.20x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alx Oncology Holdings dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 59.7M | 1.39 | - |
| 2022 | - | - | - |
| 2021 | USD 2.75M | 0.07 | - |
| 2020 | USD 3.00K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Alx Oncology Holdings
- Insiders 0.99%
- Institutions 95.82%
- Public & others 3.19%
- Shares outstanding 138M
- Free float 95.0M
Top funds holding ALXO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 8.59M | 6.21% | -0.06% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.64M | 2.63% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.54M | 1.84% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.17M | 0.85% | 0.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 1.13M | 0.82% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 932K | 0.67% | -0.38% | Oct 2026 |
| Biotech Growth Ord | 695K | 0.50% | 0.00% | Jul 2026 |
| Vanguard Russell 2000 ETF | 567K | 0.41% | -8.77% | Sep 2026 |
| Fidelity Extended Market Index | 408K | 0.29% | -0.38% | Sep 2026 |
| JPMorgan US Small Company L | 403K | 0.29% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 294K | 0.21% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 239K | 0.17% | -8.20% | Sep 2026 |
| Fidelity Total Market Index | 225K | 0.16% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 202K | 0.15% | 0.00% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 188K | 0.14% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 167K | 0.12% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 166K | 0.12% | 0.00% | Oct 2026 |
| Russell Inv US Small Cap Equity Y | 147K | 0.11% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 144K | 0.10% | 0.00% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 129K | 0.09% | +0.27% | Oct 2026 |
Top institutions holding ALXO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 13.0M | 9.41% | 0.00% | Jun 2026 |
| venBio Partners LLC | 12.9M | 9.32% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.40M | 5.35% | +1,552.42% | Jun 2026 |
| Redmile Group, LLC | 7.39M | 5.35% | -7.18% | Jun 2026 |
| Blackstone Inc | 6.59M | 4.77% | +13.16% | Jun 2026 |
| Driehaus Capital Management LLC | 6.03M | 4.36% | +5.07% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 5.74M | 4.15% | 0.00% | Jun 2026 |
| TCG Crossover Management, LLC | 5.66M | 4.09% | -56.54% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.97M | 3.60% | +18.99% | Jun 2026 |
| Vivo Capital, LLC | 3.18M | 2.30% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 3.07M | 2.22% | -18.25% | Jun 2026 |
| 5AM Venture Management, LLC | 3.06M | 2.21% | 0.00% | Jun 2026 |
| Almitas Capital LLC | 2.94M | 2.13% | -7.42% | Jun 2026 |
| Orbimed Advisors LLC | 2.87M | 2.07% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.79M | 2.02% | +464.98% | Jun 2026 |
| Two Sigma Investments LLC | 2.18M | 1.58% | +37.18% | Jun 2026 |
| Millennium Management LLC | 1.54M | 1.12% | -22.38% | Jun 2026 |
| Nantahala Capital Management, LLC | 1.50M | 1.08% | 0.00% | Jun 2026 |
| State Street Corp | 1.50M | 1.08% | +752.48% | Jun 2026 |
| Acadian Asset Management LLC | 1.31M | 0.95% | +19.30% | Jun 2026 |
Alx Oncology Holdings company profile
- Company name
- Alx Oncology Holdings
- Ticker
- ALXO.US
- Exchange
- USA Stocks
- Listed since
- Jul 17, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 48
- Fiscal year end
- December
- Address
- 323 Allerton Avenue, South San Francisco, CA, United States, 94080
- Phone
- 650 466 7125
- Website
- alxoncology.com
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Alx Oncology Holdings management
10- Mr. Jason W. LettmannCEO & Director · born 1977
- Mr. Harish Shantharam C.F.A.Chief Financial Officer · born 1981
- Ms. Shelly Wong C.P.A.Senior VP of Finance & Chief Accounting Officer · born 1976
- Dr. Barbara J. Klencke M.D.Chief Medical Officer · born 1957
- Mr. Jeff E. Knight M.P.H.Chief Development & Operating Officer · born 1971
- Mr. Michael ListgartenGeneral Counsel
- Dr. Athanasios Tsiatis M.D.Senior Vice President of Clinical Development
- Dr. Lin Yeong-Liang M.D., M.S.Senior Vice President of Drug Safety & Pharmacovigilance
- Ms. Lisa SauerSenior Vice President of Regulatory Affairs & Quality Assurance
- Ms. Venita De Almeida Ph.D.VP & Head of Research Program Development